A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

[1]  P. Abrams,et al.  Indoramin in the treatment of prostatic bladder outflow obstruction. , 1991, British journal of urology.

[2]  H. Lepor,et al.  Comparison of alpha1 Adrenoceptors in the Prostate Capsule of Men with Symptomatic and Asymptomatic Benign Prostatic Hyperplasia , 1991 .

[3]  H. Lepor,et al.  A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. , 1990, The Journal of urology.

[4]  H. Lepor,et al.  Determination of norepinephrine levels in the adult human prostate. , 1990, The Journal of urology.

[5]  A. Wein.  Evaluation of treatment response to drugs in benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[6]  Bruskewitz Rc,et al.  Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. , 1990 .

[7]  H. Lepor,et al.  The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. , 1990, The Journal of urology.

[8]  K McPherson,et al.  Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. , 1989, The New England journal of medicine.

[9]  A T Cockett,et al.  Transurethral prostatectomy: practice aspects of the dominant operation in American urology. , 1989, The Journal of urology.

[10]  U. Dunzendorfer.  Clinical experience: symptomatic management of BPH with terazosin. , 1988, Urology.

[11]  M. Dunn,et al.  Indoramin--an effective new drug in the management of bladder outflow obstruction. , 1987, British journal of urology.

[12]  H. Lepor,et al.  Alpha 1 adrenergic receptors in canine lower genitourinary tissues: insight into development and function. , 1987, The Journal of urology.

[13]  R. Kirby,et al.  Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. , 1987, British journal of urology.

[14]  N. Roos,et al.  Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. , 1987, JAMA.

[15]  I. Rutkow.  Urological operations in the United States: 1979 to 1984. , 1986, The Journal of urology.

[16]  P. Rudd.  Cumulative experience with terazosin administered in combination with diuretics. , 1986, The American journal of medicine.

[17]  H. Whitfield,et al.  A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction. , 1985, British journal of urology.

[18]  K. Andersson,et al.  Effects of prazosin in patients with benign prostatic obstruction. , 1983, The Journal of urology.

[19]  Z. Braf,et al.  Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study. , 1983, Urology.

[20]  P. Abrams,et al.  Bladder outflow obstruction treated with phenoxybenzamine. , 1982, British journal of urology.

[21]  E. Yokoyama,et al.  Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. , 1982, The Journal of urology.

[22]  T. Gerstenberg,et al.  Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation. , 1980, Investigative urology.

[23]  S. Meretyk,et al.  A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.

[24]  P. Braithwaite,et al.  Alpha‐adrenergic blockers in prostatism , 1977, The British journal of surgery.

[25]  M. Caine,et al.  The use of alpha-adrenergic blockers in benign prostatic obstruction. , 1976, British journal of urology.

[26]  P. Rigatti,et al.  Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation , 2004, Urological Research.

[27]  H. Lepor,et al.  The efficacy and safety of terazosin for the treatment of symptomatic BPH , 1991, The Prostate.

[28]  H. Lepor,et al.  Autonomic receptors in human prostate adenomas. , 1990, The Journal of urology.

[29]  J. Isaacs.  Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention , 1990, The Prostate. Supplement.

[30]  U. Dunzendorfer,et al.  Efficacy of once‐A‐day terazosin in benign prostatic hyperplasia: A randomized, double‐blind placebo‐controlled clinical trial , 1990, The Prostate. Supplement.

[31]  H. Lepor,et al.  Contractile properties of human prostate adenomas and the development of infravesical obstruction , 1989, The Prostate.

[32]  T. Niijima,et al.  Use of an α1-Blocker, YM-12617, in Micturition Difficulty , 1987 .

[33]  B. Ferrie,et al.  Phenoxybenzamine in prostatic hypertrophy. A double-blind study. , 1987, British journal of urology.

[34]  L. Edwards.  History of Nonsurgical Treatment , 1983 .

[35]  Y. Bozhok,et al.  Primary culture of prostatic region entoderm of human fetal sinus urogenitalis: Morphological, histochemical, and electrophoretic characteristics , 1982, The Prostate.

[36]  G Jones,et al.  A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. , 1976, Transactions of the American Association of Genito-Urinary Surgeons.